3-(3-fluorophenyl)-5-hexyl-1,3-oxazolidin-2-one | 1174336-04-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3-fluorophenyl)-5-hexyl-1,3-oxazolidin-2-one
• 英文别名: 3-(3-Fluorophenyl)-5-hexyloxazolidin-2-one
• CAS: 1174336-04-9
• 化学式: C₁₅H₂₀FNO₂
• 分子量: 265.328
• InChiKey: SSHCLMNCTDQOJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-己基-1,3-恶唑烷-2-酮 、 间溴氟苯 在 copper(l) iodide 、 caesium carbonate 、 trans-1,2-cyclohexanediamine 作用下， 以 1,4-二氧六环 为溶剂， 生成 3-(3-fluorophenyl)-5-hexyl-1,3-oxazolidin-2-one
  参考文献：
  名称：

  3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts

  摘要：

  Hit to lead optimization of (5R)-5-hexyl-3-phenyl-1,3-oxazolidin-2-one as a positive allosteric modulator of mGluR2 is described. Improvements in potency and metabolic stability were achieved through SAR on both ends of the oxazolidinone. An optimized lead compound was found to be brain penetrant and active in a rat ketamine-induced hyperlocomotion model for antipsychotic activity. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.03.089

文献信息

• [EN] 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES<br/>[FR] DÉRIVÉS DE 1,3-OXAZOLIDIN-2-ONE 3,5-SUBSTITUÉE
  申请人：MERCK & CO INC

  公开号：WO2009094265A1

  公开（公告）日：2009-07-30

  The present invention is directed to 3,5-disubstituted-l,3-oxazolidin~2-one derivatives which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及3,5-二取代-1,3-噁唑烷-2-酮衍生物，其是代谢型谷氨酸受体的增效剂，包括mGluR2受体，适用于治疗或预防与谷氨酸功能障碍有关的神经系统和精神疾病以及代谢型谷氨酸受体参与的疾病。该发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗涉及代谢型谷氨酸受体的疾病中的用途。
• 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES
  申请人：Brnardic Edward

  公开号：US20100292241A1

  公开（公告）日：2010-11-18

  The present invention is directed to 3,5-disubstituted-1,3-oxazolidin-2-one derivatives which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neuro-ological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及3,5-二取代-1,3-噁唑烷-2-酮衍生物，其为代谢型谷氨酸受体的增强剂，包括mGluR2受体，可用于治疗或预防与谷氨酸功能失调相关的神经学和精神疾病以及代谢型谷氨酸受体参与的疾病。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的疾病中的使用。
• 3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts
  作者：Edward J. Brnardic、Mark E. Fraley、Robert M. Garbaccio、Mark E. Layton、John M. Sanders、Chris Culberson、Marlene A. Jacobson、Brian C. Magliaro、Pete H. Hutson、Julie A. O’Brien、Sarah L. Huszar、Jason M. Uslaner、Kerry L. Fillgrove、Cuyue Tang、Yuhsin Kuo、Sylvie M. Sur、George D. Hartman

  DOI：10.1016/j.bmcl.2010.03.089

  日期：2010.5

  Hit to lead optimization of (5R)-5-hexyl-3-phenyl-1,3-oxazolidin-2-one as a positive allosteric modulator of mGluR2 is described. Improvements in potency and metabolic stability were achieved through SAR on both ends of the oxazolidinone. An optimized lead compound was found to be brain penetrant and active in a rat ketamine-induced hyperlocomotion model for antipsychotic activity. (C) 2010 Elsevier Ltd. All rights reserved.